We have recently isolated a transforming gene from the DNAS of a patient with chronic myeloid leukemia using the NIH3T3 cell focus formation assay. The sequences responsible for transformation have been cloned and characterized. The transforming gene has been identified as fibroblast growth factor 4 (FGF4). Expression of FGF4 is restricted to undifferentiated embryonic stem and embryonal carcinoma cells and is not expressed in somatic tissue. The coding sequences of the FGF4 gene (located on chromosome 11) have been fused to RNA processing signals from an unidentified gene on chromosome 15. Transformation by FGF4 in this and previously described studies is the result of deregulated expression rather than mutation of the coding sequences. It is therefore of value to investigate the mechanism of regulation of FGF4 expression. Paradoxically, expression of endogenous FGF4 is suppressed in NIH3T3 cells yet an exogenously added copy of the normal gene is expressed and capable of inducing transformation. The goals of the proposed study are threefold. Firstly we wish to further previous studies and investigate the mechanism of local control of FGF4 expression. Specifically, to date the promoter has been shown to be inactive in all cell lines tested unless linked to an activating 3' enhancer sequence. Study of functional promoter domains has thus proven difficult. Using a transient reporter assay system (luciferase) which is more sensitive than the system (CAT) used previously by others, we have identified active promoter domains within the 5' flanking sequence of FGF4 and have shown the promoter to be active in both embryonal carcinoma cells (F9) which are permissive for FGF4 expression and HeLa cells which are not. We wish to further these studies and characterize functional domains both within the promoter and the enhancer sequence and to investigate how such sequences might interact to control local expression of FGF4. Secondly, based on previous data demonstrating that cosmid clones harboring the FGF4 gene are transforming while the endogenous gene is silent, we suggest the possibility that FGF4 expression may also be regulated from a distant locus. We will investigate this possibility by the transfer into NIH3T3 cells of YAC clones containing the FGF4 gene. These clones will therefore contain substantially greater sequence flanking the FGF4 gene than clones previously described. If transfer of YACs produce cell colonies of normal rather than transformed morphology, it may be inferred that a putative suppressor locus has been co-transferred and this locus will then be further characterized. Thirdly, little is known about the genes which are activated in response to FGF4 induced transformation of NIH3T3 cells. We will attempt to identify and characterize these genes by utilizing a recent and novel PCR based method which allows the identification and cloning of cDNA from differentially expressed genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA063134-05
Application #
2700541
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Gallahan, Daniel L
Project Start
1994-05-01
Project End
2001-04-30
Budget Start
1998-05-01
Budget End
2001-04-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Ohio State University
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sedghizadeh, Parish P; Mallery, Susan R; Thompson, Sarah J et al. (2006) Expression of the serine protease DESC1 correlates directly with normal keratinocyte differentiation and inversely with head and neck squamous cell carcinoma progression. Head Neck 28:432-40
Lang, J C; Borchers, J; Danahey, D et al. (2002) Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF. Int J Oncol 21:401-8
Lang, J C; Schuller, D E (2001) Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer 84:237-43
Danahey, D G; Tobin, E J; Schuller, D E et al. (1999) p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 119:285-8
Lang, J C; Tobin, E J; Knobloch, T J et al. (1998) Frequent mutation of p16 in squamous cell carcinoma of the head and neck. Laryngoscope 108:923-8
Kenny, J J; Knobloch, T J; Augustus, M et al. (1997) GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes. Oncogene 14:997-1001
Gramza, A W; Lucas, J M; Mountain, R E et al. (1995) Efficient method for preparing normal and tumor tissue for RNA extraction. Biotechniques 18:228-31
Bryans, M; Lucas, J M; Knobloch, T J et al. (1995) Regulation of FGF-4 enhancer activity by transcription factor NF-Y. Biochem Biophys Res Commun 211:519-27